XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Friday.

Separately, HC Wainwright restated a “buy” rating and set a $104.00 price objective on shares of XOMA in a report on Wednesday.

XOMA Stock Performance

Shares of NASDAQ:XOMA traded down $0.18 during trading on Friday, reaching $20.88. 81,363 shares of the stock were exchanged, compared to its average volume of 26,540. XOMA has a 12 month low of $19.92 and a 12 month high of $35.00. The firm has a market cap of $250.12 million, a PE ratio of -6.00 and a beta of 1.00. The stock has a 50-day moving average price of $24.37 and a 200-day moving average price of $27.14. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. Research analysts expect that XOMA will post -1.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares in the last quarter. Barclays PLC lifted its stake in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after acquiring an additional 8,447 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the last quarter. State Street Corp boosted its holdings in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.